Zosano Appoints Georgia Erbez as Chief Business Officer

FREMONT, Calif., Sept. 08, 2016 -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’s proprietary transdermal delivery system, today announced the appointment of Ms. Georgia Erbez as its Chief Business Officer, effective September 8, 2016. Ms. Erbez will continue to serve as Zosano’s Interim Chief Financial Officer.

“We are excited to appoint Georgia to the Chief Business Officer position. Her extensive experience in senior management roles in the healthcare sector will be instrumental as we continue to advance the development of M207 for the treatment of acute migraine,” commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma.  

Ms. Erbez has served as Interim Chief Financial Officer of Zosano since June 2016 and through the years, has provided financial and strategic consultancy to multiple biotechnology companies. Previous experience includes serving as Chief Financial Officer and Executive Vice President of Asterias Biotherapeutics, Inc. and Chief Financial Officer, Secretary and Treasurer of Raptor Pharmaceuticals, where she helped to navigate the company through a growth period that included its first drug approval and subsequent commercial launch.  Prior to Raptor, Ms. Erbez was a Managing Director, Healthcare Investment Banking at Collins Stewart, a senior level investment banker at Beal Advisors, Jeffries & Company, Inc. and Cowen and Company.  She has also held positions at the investment banks Hambrecht & Quist and Alex, Brown & Sons Inc.  Ms. Erbez received a Bachelor of Arts degree, International Relations from the University of California at Davis.

About Zosano Pharma

Zosano Pharma Corporation is an emerging CNS company focusing on providing rapid symptom relief to patients using known therapeutics and altering their delivery profile using the Company’s proprietary transdermal delivery system. The Company’s goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.  The Company believes that its transdermal delivery system offers rapid and consistent drug delivery combined with ease of use.  The Company is focused on developing products that deliver established molecules with known safety and efficacy profiles for markets where patients remain underserved by existing therapies.  Zosano Pharma anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, including the timeline for pivotal efficacy data, our ability to obtain necessary regulatory approvals and other future events and expectations. Readers are urged to consider statements that include the words "expects," "continues," "believes," "potential," “goal,” "may," "will," "would," "could," "should," "might," "estimates," "projects," "plans," "anticipates," "intends," "forecast," "designed," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in our 2015 Annual Report on Form 10-K, as filed with the Securities Exchange Commission on March 29, 2016. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
Konstantinos Alataris, Ph.D.
Chief Executive Officer
510-745-1200

Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
[email protected]